New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareKPV vs Cagrilintide

KPV vs Cagrilintide

Side-by-side comparison of key properties, dosing, and research.

Immune SupportRecovery & Repair
KPV
GLP-1 / Weight Loss Agonists
Cagrilintide
Summary
KPV is a naturally occurring anti-inflammatory tripeptide derived from the C-terminal of alpha-MSH. It powerfully suppresses intestinal and systemic inflammation via melanocortin receptors, making it valuable for IBD, gut healing, and wound repair.
Cagrilintide is a long-acting amylin analog developed by Novo Nordisk. Amylin is a peptide hormone co-secreted with insulin from pancreatic beta cells. Cagrilintide slows gastric emptying, suppresses glucagon, and reduces appetite via central amylin receptors. In combination with semaglutide (CagriSema), Phase 2 trials achieved approximately 15% body weight reduction. Phase 3 trials (REDEFINE program) are ongoing.
Half-Life
Short half-life (~15–30 minutes), but effects persist longer due to receptor-level anti-inflammatory cascades
~7–10 days
Admin Route
Oral, SubQ, Topical
SubQ
Research
Typical Dose
500 mcg – 1 mg
0.16 mg → 0.3 mg → 0.6 mg → 1.2 mg → 2.4 mg
Frequency
Once to twice daily
Once weekly
Key Benefits
  • Reduces intestinal inflammation (IBD, Crohn's, colitis)
  • Promotes gut mucosal healing and barrier integrity
  • Accelerates wound healing topically
  • Suppresses systemic inflammatory cytokines
  • Antimicrobial properties against pathogens
  • Reduces neuroinflammation when administered systemically
  • May improve symptoms of inflammatory skin conditions
  • ~15% body weight reduction in combination with semaglutide (CagriSema Phase 2)
  • Synergistic appetite suppression complementing GLP-1 receptor agonists
  • Reduces post-meal glucagon excursions improving glycemic control
  • Slows gastric emptying contributing to prolonged satiety
  • Once-weekly dosing via subcutaneous injection
  • Potential for greater weight loss than semaglutide monotherapy
Side Effects
  • Generally very well tolerated
  • Mild injection site reactions (SC)
  • Rare: transient flushing
  • Nausea (most common, especially during titration)
  • Vomiting
  • Decreased appetite
  • Diarrhea
  • +2 more
Stacks With